Corient Private Wealth
OTLK icon

Corient Private Wealth’s Outlook Therapeutics OTLK Stock Holding History

Corient Private Wealth’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2K Buy
+30,100
New +$13K ﹤0.01% 2807
2024
Q1 		– Sell
-2,700
Closed -$21.3K – 2340
2023
Q4 		$21.3K Hold
2,700
– – ﹤0.01% 2221
2023
Q3 		$11.9K Buy
2,700
+1,700
+170% +$37.6K ﹤0.01% 2119
2023
Q2 		$34.8K Sell
1,000
-1,450
-59% -$39.5K ﹤0.01% 2036
2023
Q1 		$53.4K Buy
2,450
+1,000
+69% +$22.4K ﹤0.01% 1934
2022
Q4 		$31.3K Buy
+1,450
New +$31.5K ﹤0.01% 1653

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Corient Private Wealth's OTLK Position: Q1 2026 in Review

Corient Private Wealth opened a new position in Outlook Therapeutics (OTLK) in Q1 2026: 30,100 shares worth $6.2K. The stake represents ﹤0.01% of the portfolio and ranks #2807 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in OTLK as recently as Q4 2023.

Corient Private Wealth first reported a position in OTLK in Q4 2022 and has held it in 6 quarters since. The position peaked at $53.4K in Q1 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Corient Private Wealth held 30,100 shares of Outlook Therapeutics worth $6.2K as of Q1 2026.
  • Outlook Therapeutics was a new Corient Private Wealth position in Q1 2026.
  • Outlook Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2807 holding.
  • Corient Private Wealth first reported a position in Outlook Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • Corient Private Wealth's Outlook Therapeutics position peaked at $53.4K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.